Contineum Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CTNM$10.30+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(59,978) | $(42,258) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 323 | 258 |
| Non-cash operating lease expense | 1,080 | 872 |
| Stock-based compensation | 10,038 | 6,804 |
| Accretion of premiums/discounts on marketable securities, net | (791) | (3,940) |
| Loss (gain) on sale of property and equipment | 67 | (16) |
| Change in fair value of warrant liability | — | 106 |
| Gain on marketable securities | (12) | (5) |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | (3,396) | 887 |
| Other long-term assets | 3 | 937 |
| Accounts payable | (869) | 1,141 |
| Accrued expenses | (516) | 2,303 |
| Operating lease liabilities | (1,261) | 66 |
| Net cash used in operating activities | (55,312) | (32,845) |
| Investing activities | ||
| Purchase of property and equipment | (231) | (514) |
| Proceeds from sale of equipment | — | 20 |
| Purchases of marketable securities | (162,502) | (226,407) |
| Sales and maturities of marketable securities | 159,020 | 157,162 |
| Net cash used in investing activities | (3,713) | (69,739) |
| Financing activities | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | — | 108,211 |
| Payments of deferred offering costs | (256) | — |
| Proceeds from issuance of common stock in at-the-market offering, net of offering costs | 19,012 | — |
| Proceeds from issuance of common stock in follow-on public offering, net of offering costs | 93,243 | — |
| Proceeds from exercise of stock options | 219 | 405 |
| Proceeds from employee stock purchase plan | 467 | 385 |
| Net cash provided by financing activities | 112,685 | 109,001 |
| Net increase in cash and cash equivalents | 53,660 | 6,417 |
| Cash and cash equivalents at beginning of year | 21,943 | 15,526 |
| Cash and cash equivalents at end of year | $75,603 | $21,943 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Property and equipment purchases included in accounts payable | $— | $58 |
| Conversion of convertible preferred stock to common stock upon initial public offering | $— | $192,620 |
| Reclassification of warrants from liability to equity | $— | $216 |
| Reclassification of deferred offering costs paid in prior year to equity | $— | $343 |
| Right-of-use assets obtained in exchange for lease liabilities | $3,252 | $5,620 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.